Singapore, March 21 -- In response to the growing burden of prostate cancer in Taiwan, Primo Biotechnology has formed a strategic partnership with Germany-based ABX advanced biochemical compounds GmbH (ABX) to lay the groundwork for introducing PB01 to the Taiwanese market.

Data from Taiwan Cancer Registry indicate a steady increase in both, the incidence and mortality of prostate cancer, in recent years, underscoring the urgent demand for more accurate diagnostic tools.

Radelumin, an innovative diagnostic radiotracer tailored specifically for prostate cancer patients, has already gained approval in France and multiple European countries. Using advanced PET/CT imaging technology, Radelumin and its equivalent for the Taiwanese market, PB...